Wedbush analyst David Nierengarten reiterated an Outperform rating on Perspective Therapeutics (CATX) and kept a 12-month price target of $11. The note is supportive but contains no new operational data, so the likely market impact is limited to analyst-driven sentiment.
Wedbush analyst David Nierengarten reiterated an Outperform rating on Perspective Therapeutics (CATX) and kept a 12-month price target of $11. The note is supportive but contains no new operational data, so the likely market impact is limited to analyst-driven sentiment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
